Clinical trial of thymosin α1 combined with XELOX regimen in the treatment of patients with colorectal cancer surgery
10.13699/j.cnki.1001-6821.2024.19.008
- VernacularTitle:胸腺肽α1联合XELOX方案治疗结直肠癌术患者的临床研究
- Author:
Xiao-Dong REN
1
;
Zhen HU
;
Chao-Yi LI
;
Yao-Ping LI
Author Information
1. 山西省人民医院结直肠肛门外科,山西太原 030000
- Keywords:
thymosin α1 injection;
colorectal cancer;
circulating tumor cell;
carcinoembryonic antigen;
serum carbohydrate antigen 19-9;
serum carbohydrate antigen 125
- From:
The Chinese Journal of Clinical Pharmacology
2024;40(19):2796-2800
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the influence of thymosin α1 injection combined with capecitabine and oxaliplatin(XELOX)regimen on circulating tumor cell(CTC)and serum carcinoembryonic antigen(CEA),serum carbohydrate antigen 19-9(CA19-9)and CA125 levels in patients with colorectal cancer surgery.Methods Patients who received laparoscopic radical resection of colorectal cancer were divided into control group and treatment group by adopting cohort method.The control group was treated with XELOX regimen adjuvant chemotherapy;and on the 1st day,135 mg·m-2of oxaliplatin was intravenously dripped for 3 h;and capecitabine tablets were taken orally at 1 000 mg·m-2 twice a day for 2 weeks and discontinued for 1 week.On the basis of the treatment in the control group,the treatment group was added with subcutaneous injection of 1.6 mg of thymosin α1 once a day.Both groups were treated for 6 courses with 3 weeks as a course of treatment.CTC count,serum tumor markers,peripheral blood T lymphocyte subsets,serum inflammatory factors,quality of life,safety and progression-free survival rate and overall survival rate at 2 years after surgery were compared between groups.Results Finally,56 cases in treatment group and 50 cases in control group were included.The progression-free survival rates in treatment group and control group at 2 years after surgery were 87.50％(49 cases/56 cases)and 70.00％(35 cases/50 cases),respectively(P＜0.05).After treatment,the CTC counts in treatment group and control group were 1.21±0.39 and 1.52±0.46;serum CEA levels were(18.52±4.17)and(23.26±4.84)μg·L-1;the CA19-9 levels were(63.94±10.22)and(69.73±12.35)U·L-1;the CA125 level were(40.66±9.29)and(46.79±10.24)U·L-1;the peripheral blood CD4+/CD8+ratios were(1.38±0.18)and(1.24±0.16);serum interleukin-6(IL-6)levels were(32.04±5.57)and(37.26±6.18)ng·L-1;tumor necrosis factor-α(TNF-α)levels were(43.96±4.83)and(51.83±5.97)ng·L-1;the Karnofsky performance status(KPS)scores were(86.77±6.91)and(82.23±5.32)points;the cancer quality of life core 30(QLQ-C30)scores were(69.12±9.76)and(75.06±9.84)points(all P＜0.05).During treatment,the neutropenia rates in treatment group and control group were 48.21％and 76.00％,and abnormal rates of liver function were 10.71％and 40.00％,respectively(all P＜0.05).Conclusion Thymosin α1 injection combined with XELOX regimen adjuvant chemotherapy after colorectal cancer surgery can effectively reduce the levels of serum CEA,CA19-9 and CA125,and can improve the cellular immune function and enhance the quality of life.
